IBDEI0JM ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9114,2)
 ;;=^5005659
 ;;^UTILITY(U,$J,358.3,9115,0)
 ;;=H35.361^^41^474^20
 ;;^UTILITY(U,$J,358.3,9115,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9115,1,3,0)
 ;;=3^Drusen of Macular,Right Eye
 ;;^UTILITY(U,$J,358.3,9115,1,4,0)
 ;;=4^H35.361
 ;;^UTILITY(U,$J,358.3,9115,2)
 ;;=^5005658
 ;;^UTILITY(U,$J,358.3,9116,0)
 ;;=H04.123^^41^474^21
 ;;^UTILITY(U,$J,358.3,9116,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9116,1,3,0)
 ;;=3^Dry Eye Syndrome,Bilateral Lacrimal Glands
 ;;^UTILITY(U,$J,358.3,9116,1,4,0)
 ;;=4^H04.123
 ;;^UTILITY(U,$J,358.3,9116,2)
 ;;=^5004465
 ;;^UTILITY(U,$J,358.3,9117,0)
 ;;=H35.32^^41^474^28
 ;;^UTILITY(U,$J,358.3,9117,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9117,1,3,0)
 ;;=3^Exudative Age-Related Macular Degeneration
 ;;^UTILITY(U,$J,358.3,9117,1,4,0)
 ;;=4^H35.32
 ;;^UTILITY(U,$J,358.3,9117,2)
 ;;=^5005648
 ;;^UTILITY(U,$J,358.3,9118,0)
 ;;=H35.023^^41^474^29
 ;;^UTILITY(U,$J,358.3,9118,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9118,1,3,0)
 ;;=3^Exudative Retinopathy,Bilateral
 ;;^UTILITY(U,$J,358.3,9118,1,4,0)
 ;;=4^H35.023
 ;;^UTILITY(U,$J,358.3,9118,2)
 ;;=^5005588
 ;;^UTILITY(U,$J,358.3,9119,0)
 ;;=H35.022^^41^474^30
 ;;^UTILITY(U,$J,358.3,9119,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9119,1,3,0)
 ;;=3^Exudative Retinopathy,Left Eye
 ;;^UTILITY(U,$J,358.3,9119,1,4,0)
 ;;=4^H35.022
 ;;^UTILITY(U,$J,358.3,9119,2)
 ;;=^5005587
 ;;^UTILITY(U,$J,358.3,9120,0)
 ;;=H35.021^^41^474^31
 ;;^UTILITY(U,$J,358.3,9120,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9120,1,3,0)
 ;;=3^Exudative Retinopathy,Right Eye
 ;;^UTILITY(U,$J,358.3,9120,1,4,0)
 ;;=4^H35.021
 ;;^UTILITY(U,$J,358.3,9120,2)
 ;;=^5005586
 ;;^UTILITY(U,$J,358.3,9121,0)
 ;;=H40.013^^41^474^32
 ;;^UTILITY(U,$J,358.3,9121,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9121,1,3,0)
 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Bilateral
 ;;^UTILITY(U,$J,358.3,9121,1,4,0)
 ;;=4^H40.013
 ;;^UTILITY(U,$J,358.3,9121,2)
 ;;=^5005726
 ;;^UTILITY(U,$J,358.3,9122,0)
 ;;=H40.012^^41^474^33
 ;;^UTILITY(U,$J,358.3,9122,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9122,1,3,0)
 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Left Eye
 ;;^UTILITY(U,$J,358.3,9122,1,4,0)
 ;;=4^H40.012
 ;;^UTILITY(U,$J,358.3,9122,2)
 ;;=^5005725
 ;;^UTILITY(U,$J,358.3,9123,0)
 ;;=H40.011^^41^474^34
 ;;^UTILITY(U,$J,358.3,9123,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9123,1,3,0)
 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Right Eye
 ;;^UTILITY(U,$J,358.3,9123,1,4,0)
 ;;=4^H40.011
 ;;^UTILITY(U,$J,358.3,9123,2)
 ;;=^5005724
 ;;^UTILITY(U,$J,358.3,9124,0)
 ;;=H52.03^^41^474^41
 ;;^UTILITY(U,$J,358.3,9124,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9124,1,3,0)
 ;;=3^Hypermetropia,Bilateral
 ;;^UTILITY(U,$J,358.3,9124,1,4,0)
 ;;=4^H52.03
 ;;^UTILITY(U,$J,358.3,9124,2)
 ;;=^5006262
 ;;^UTILITY(U,$J,358.3,9125,0)
 ;;=H52.02^^41^474^42
 ;;^UTILITY(U,$J,358.3,9125,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9125,1,3,0)
 ;;=3^Hypermetropia,Left Eye
 ;;^UTILITY(U,$J,358.3,9125,1,4,0)
 ;;=4^H52.02
 ;;^UTILITY(U,$J,358.3,9125,2)
 ;;=^5006261
 ;;^UTILITY(U,$J,358.3,9126,0)
 ;;=H52.01^^41^474^43
 ;;^UTILITY(U,$J,358.3,9126,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9126,1,3,0)
 ;;=3^Hypermetropia,Right Eye
 ;;^UTILITY(U,$J,358.3,9126,1,4,0)
 ;;=4^H52.01
 ;;^UTILITY(U,$J,358.3,9126,2)
 ;;=^5006260
 ;;^UTILITY(U,$J,358.3,9127,0)
 ;;=H59.41^^41^474^44
 ;;^UTILITY(U,$J,358.3,9127,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9127,1,3,0)
 ;;=3^Inflammation of Postprocedural Bleb,Stage 1
